Multivessel drug-eluting stenting and impact of diabetes mellitus - A report from the EVENT registry

Catheterization and Cardiovascular Interventions

Volumn 73, Issue 7, 2009, Pages 874-880

  Novack, Victor ^a   Tsyvine, Daniel ^b   Cohen, David J ^c   Pencina, Michael ^a   Dubin, Joseph ^b   Dehghani, Hossein ^b   Kleiman, Neal S ^d   Cutlip, Donald E ^a,b  

^a HARVARD CLINICAL RESEARCH INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c SAINT LUKE S MID AMERICA HEART INSTITUTE   (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Diabetes; Restenosis; Stent

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN;

ADULT; ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; DRUG ELUTING STENT; DYSLIPIDEMIA; FEMALE; FOLLOW UP; HEART EJECTION FRACTION; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; HYPERTENSION; IN-STENT RESTENOSIS; INDEPENDENT VARIABLE; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PATIENT SAFETY; PERCUTANEOUS CORONARY INTERVENTION; PREVALENCE; PROPORTIONAL HAZARDS MODEL; REGISTER; SEX DIFFERENCE; TREATMENT RESPONSE;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CARDIOVASCULAR DISEASES; CORONARY ARTERY DISEASE; CORONARY THROMBOSIS; DIABETES COMPLICATIONS; DRUG-ELUTING STENTS; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; REGISTRIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 68249142767     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.21925     Document Type: Article

References (25)

1. Carrozza JP Jr, Kuntz RE, Fishman RF, Baim DS. Restenosis after arterial injury caused by coronary stenting in patients with diabetes mellitus. Ann Intern Med 1993;118:344-349.
2. Stein B, Weintraub WS, Gebhart SP, Cohen-Bernstein CL, Grosswald R, et al. Influence of diabetes mellitus on early and late outcome after percutaneous transluminal coronary angioplasty. Circulation 1995;91:979-989.
3. Kip KE, Faxon DP, Detre KM, Yeh W, Kelsey SF, et al. Coronary angioplasty in diabetic patients. The National Heart, Lung, and Blood Institute percutaneous transluminal coronary angioplasty registry. Circulation 1996;94:1818-1825.
4. Laskey WK, Selzer F, Vlachos HA, Johnston J, Jacobs A, et al. Comparison of in-hospital and one-year outcomes in patients with and without diabetes mellitus undergoing percutaneous catheter intervention (from the National Heart, Lung, and Blood Institute dynamic registry). Am J Cardiol 2002;90:1062-1067.
5. Lee TT, Feinberg L, Baim DS, Holmes DR, Aroesty JM, et al. Effect of diabetes mellitus on five-year clinical outcomes after single-vessel coronary stenting (a pooled analysis of coronary stent clinical trials). Am J Cardiol 2006;98:718-721.
6. The Bypass Angioplasty Revascularization Investigation (BARI) investigators. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. N Engl J Med 1996;335:217-225.
7. The BARI investigators. Influence of diabetes on 5-year mortality and morbidity in a randomized trial comparing CABG and PTCA in patients with multivessel disease: The Bypass Angioplasty Revascularization Investigation (BARI). Circulation 1997; 96:1761-1769.
8. King SB III, Kosinski AS, Guyton RA, Lembo NJ, Weintraub WS. Eight-year mortality in the Emory Angioplasty versus Surgery Trial (EAST). J Am Coll Cardiol 2000;35:1116-1121.
9. Serruys PW, Ong AT, van Herwerden LA, Sousa JE, Jatene A, et al. Five-year outcomes after coronary stenting versus bypass surgery for the treatment of multivessel disease: The final analysis of the Arterial Revascularization Therapies Study (ARTS) randomized trial. J Am Coll Cardiol 2005;46:575-581.
10. Smith SJ, Feldman T, Hirshfeld JJ, Jacobs A, Kern M, et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (ACC/AHA/SCAI writing committee to update the 2001 guidelines for percutaneous coronary intervention). American College of © 2005 by the American College of Cardiology Foundation and the American Heart Association Inc. Cardiology web site. Available at: http://www.acc.org/clinical/guidelines/percutaneous/update/index.pdf. 2005.
11. Flaherty JD, Davidson CJ. Diabetes and coronary revascularization. JAMA 2005;293:1501-1508.
12. Jacob S, Cohen DJ, Massaro J, Niemyski P, Maresh K, et al. Design of a registry to characterize "real-world" outcomes of percutaneous coronary revascularization in the drug-eluting stent era. Am Heart J 2005;150:887-892.
13. Win HK, Caldera AE, Maresh K, Lopez J, Rihal CS, et al. Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents. JAMA 2007;297:2001-2009.
14. Bravata DM, Gienger AL, McDonald KM, Sundaram V, Perez MV, et al. Systematic review: The comparative effectiveness of percutaneous coronary interventions and coronary artery bypass graft surgery. Ann Intern Med 2007;147:703-716.
15. Lemos PA, Serruys PW, van Domburg RT, Saia F, Arampatzis CA, et al. Unrestricted utilization of sirolimus-eluting stents compared with conventional bare stent implantation in the "real world": The Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry. Circulation 2004; 109:190-195.
16. Moussa I, Leon MB, Baim DS, O'Neill WW, Popma JJ, et al. Impact of sirolimus-eluting stents on outcome in diabetic patients: A SIRIUS (SIRolImUS-coated Bx velocity balloon-expandable stent in the treatment of patients with de novo coronary artery lesions) substudy. Circulation 2004;109:2273-2278.
17. Hermiller JB, Raizner A, Cannon L, Gurbel PA, Kutcher MA, et al. Outcomes with the polymer-based paclitaxel-eluting TAXUS stent in patients with diabetes mellitus: The TAXUS-IV trial. J Am Coll Cardiol 2005;45:1172-1179.
18. Serruys PW, Ong ATL, Morice MC, De Bruyne B, Colombo A, et al. Arterial revascularisation therapies study part II - Sirolimus-eluting stents for the treatment of patients with multivessel de novo coronary artery lesions. EuroInterv 2005;1:147-156.
19. Kuntz RE. Importance of considering atherosclerosis progression when choosing a coronary revascularization strategy: The diabetes-percutaneous transluminal coronary angioplasty dilemma. Circulation 1999;99:847-851.
20. Maisel WH. Unanswered questions - Drug-eluting stents and the risk of late thrombosis. N Engl J Med 2007;356:981-984.
21. Laskey WK, Yancy CW, Maisel WH. Thrombosis in coronary drug-eluting stents: Report from the meeting of the Circulatory System Medical Devices Advisory Panel of the Food and Drug Administration Center for Devices and Radiologic Health, December 7-8, 2006. Circulation 2007;115:2352-2357.
22. Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005;293:2126-2130.
23. Daemen J, Wenaweser P, Tsuchida K, Vaina S, Abrecht L, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: Data from a large two-institutional cohort study. Lancet 2007;369:667-678.
24. Chauhan MS, Ho KK, Baim DS, Kuntz RE, Cutlip DE. Effect of gender on in-hospital and one-year outcomes after contemporary coronary artery stenting. Am J Cardiol 2005;95:101-104.
25. Lansky AJ, Costa RA, Mooney M, Midei MG, Lui HK, et al. Gender-based outcomes after paclitaxel-eluting stent implantation in patients with coronary artery disease. J Am Coll Cardiol 2005;45:1180-1185.